Related Experiment Video
Updated: Aug 6, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
Published on: October 17, 2025
Industrialization of Bayesian decision-making for proof-of-commercial-concept study designs
Fan Wu1, Pascal Minini2, Gang Han1
1Evidence Generation and Decision Science, Sanofi, Morristown, NJ, USA.
HERALD, a Bayesian decision-making framework, predicts Phase 3 success at the proof-of-commercial-concept stage. Industrializing HERALD streamlines decision-making and enhances cross-functional team communication for drug development.
Area of Science:
- Clinical trial design
- Pharmaceutical decision-making
- Bayesian statistics
Background:
- The Holistic Evolving ReAssessment-Leveraged Decision-making (HERALD) framework utilizes Bayesian principles.
- HERALD focuses on predicting Phase 3 clinical trial success.
- This framework is crucial for optimizing drug development strategies.
Purpose of the Study:
- To describe the industrialization of the HERALD framework at the proof-of-commercial-concept (POCC) study design stage.
- To demonstrate how HERALD integrates Phase 3 assumptions with POCC data for decision-making.
- To enhance the efficiency of communication within cross-functional teams during study design.
Main Methods:
- Development of specialized statistical software for HERALD implementation.
- Standardization of governance presentations for clear communication.
- Consolidation of diverse implementation examples for practical application.
- Implementation of role-tailored training programs for effective user engagement.
Main Results:
- HERALD provides decision boundaries ensuring a high probability of Phase 3 success.
- The framework has been widely adopted and endorsed across therapeutic areas at Sanofi.
- Industrialization has streamlined the discussion of decision-making criteria.
- Empowered statisticians and non-statisticians to communicate design options more effectively.
Conclusions:
- Industrialized HERALD enhances decision-making efficiency in early-stage drug development.
- Standardized processes and training facilitate better communication and collaboration.
- The framework supports robust decision-making by linking early-stage data to late-stage success probabilities.
Related Concept Videos
Study Design in Statistics
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
Decision Making: P-value Method
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
Decision Making: Traditional Method
First, a specific claim about the population parameter is decided based on the research question and is stated in a simple form. Further, an opposing statement to this claim is also stated. These statements can act as null and alternative hypotheses, out of which a null hypothesis would be a...
Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data
Parametric statistics, as the name suggests, assumes that data follow a specific distribution, often a normal distribution. This assumption enables robust hypothesis testing and estimation. Parametric methods, like the Student's t-test or Goodness-of-fit test, are frequently employed in biostatistics due to their robustness. For instance, comparing...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Experimental Designs